« Zurück
Startseite /
Ursodeoxycholic acid (Standard)

Ursodeoxycholic acid (Standard)

ArtNr	HY-13771R-250mg
Hersteller	MedChem Express
CAS-Nr.	128-13-2
Menge	250 mg
Quantity options	1 ea 100 mg 250 mg 25 mg 50 mg
Kategorie	Reagents & Chemicals Standards, Ladders & Markers Other Standards
Typ	Standard
Specific against	other
Citations	[1]Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46(4):1131-7.\|[2]Kumar D, et al. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16(1):3-14.\|[3]Biao Nie, et al. Specific Bile Acids Inhibit Hepatic Fatty Acid Uptake in Mice. Hepatology. 2012 Oct;56(4):1300-10.\|[4]Brevini T, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022 Dec 5.\|[5]Winston JA, et al. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021;16(2):e0246161. Published 2021 Feb 18.
Smiles	C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
ECLASS 10.1	42021590
ECLASS 11.0	42021590
UNSPSC	12352202
Alias	Ursodeoxycholate (Standard),Ursodiol (Standard),UDCA (Standard)
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference Standards
Manufacturer - Targets	Angiotensin-converting Enzyme (ACE); Endogenous Metabolite; FXR; G protein-coupled Bile Acid Receptor 1; Reference Standards
Shipping Temperature	Room temperature
Molecular Weight	392.57
Product Description	Ursodeoxycholic acid (Standard) is the analytical standard of Ursodeoxycholic acid. This product is intended for research and analytical applications. Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active[1][2][3][4].
Manufacturer - Research Area	Cancer; Infection; Metabolic Disease
Manufacturer - Pathway	GPCR/G Protein; Metabolic Enzyme/Protease; Others

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

Sicherheitsdatenblatt anfordern

Einfache Bestellung Periodische Bestellung

Menge: 250 mg

lieferbar

Technische Frage stellen